Most smokers who attempt to quit lapse within the first week and are ultimately unsuccessful in their quit attempt. Nicotine withdrawal exacerbates cognitive and attentional problems and may be one factor in smoking relapse. The startle reflex response and prepulse inhibition (PPI) of the response are sensitive to arousal and early attentional dysregulation. The current study examined whether startle response and PPI are related to early smoking lapse, and if this differs in people with and without posttraumatic stress disorder (PTSD). Participants with (N = 34) and without (N = 57) PTSD completed a startle reflex and PPI assessment during (1) ad lib smoking (2) on the first day of abstinence during a quit attempt. Most (88%) participants lapsed within the first week of the quit attempt. PTSD status predicted shorter time to lapse. Larger startle magnitude and greater PPI predicted a longer duration before smoking lapse. When diagnostic groups were examined separately, greater PPI predicted a longer successful quit attempt only in participants with a PTSD diagnosis. The startle reflex response and PPI may provide an objective, neurophysiological evaluation of regulation of arousal and early attentional processes by nicotine, which are important factors in smoking cessation success.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586071 | PMC |
http://dx.doi.org/10.1177/0269881115598319 | DOI Listing |
Public Health Pract (Oxf)
June 2025
Department of Psychiatry, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Background: Shared decision-making (SDM) incorporates evidence, patient values, and preferences into medical decision-making. SDM and decision aids might promote health professional engagement and patient knowledge of tobacco cessation therapy, improving usage and results. The SDM facilitates talks that lead to better-informed judgements that align with patients' priorities, unlike individual decision-making.
View Article and Find Full Text PDFArthritis Care Res (Hoboken)
January 2025
Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX.
Objective: In this study, we explored physicians' level of experience with patients with rheumatoid arthritis (RA) who used tobacco; their views on the effects of tobacco use on the efficacy of RA treatments; and their experiences and attitudes with respect to tobacco cessation programs.
Methods: We conducted qualitative, semi-structured interviews of 20 physicians (10 primary-care physicians [PCPs] and 10 rheumatologists).
Results: The physicians had been in clinical practice for a mean of 9.
JAMA Netw Open
January 2025
Department of Behavioural Science and Health, University College London, London, United Kingdom.
Importance: A wide range of medications, noncombustible nicotine products, behavioral support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness outside of clinical trial settings can support informed decision-making.
Objectives: To provide up-to-date estimates of the prevalence of different smoking cessation aids and associations with quit success and to explore moderation by socioeconomic position.
Health Promot Chronic Dis Prev Can
January 2025
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
An analysis of 1771 Canadian adults who smoke or used to smoke cigarettes was conducted using data from the 2022 International Tobacco Control Four Country Smoking and Vaping Survey. Using weighted data, we estimated the prevalence of Canadian adults who tried to quit smoking between 2020 and 2022, and the use of a nicotine vaping product (NVP) and the flavours and devices used most often at their most recent quit attempt. Overall, 36.
View Article and Find Full Text PDFTob Prev Cessat
January 2025
Institute of Primary Health Care, University of Bern, Bern, Switzerland.
Introduction: Many tobacco smokers try to quit with electronic nicotine delivery systems (ENDS or e-cigarettes). We aimed to describe e-liquid flavors and nicotine concentration use over 6 months in a prospective cohort of smokers willing to quit with ENDS.
Methods: We included 622 participants from the intervention group of the Efficacy, Safety and Toxicology of ENDS randomized controlled trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!